Geneva, Switzerland (PRWEB) November 19, 2013
Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the hire of Marco Bocci, PhD, DPharm, as Director of European Sales and Business Development. Dr. Bocci joins Selexis from Quintiles and will be responsible for growing and managing sales and business development in Europe.
“With the recent launch of our SURE CHO-Mplus Libaries, Selexis is now well positioned to meet our customers biologic development needs from discovery to commercial manufacturing,” said Dr. Igor Fisch, CEO of Selexis SA. “The addition of Marco to our leadership team underscores our commitment to helping our customers discover and commercialize biologic therapeutics. Marco’s knowledge of the CRO field and the scientific skills he acquired at the University of Cambridge are the right fit for our growing technology platform and customer base.”
Dr. Bocci brings a proven track record in business development, sales and clinical development. With over 15 years of experience in life sciences, Dr. Bocci has extensive international business, product development and regulatory knowledge gained within the biotechnology and clinical research industries. Prior to joining Selexis, he was with Quintiles Outcome as Business Development Director where he focused on increasing European market penetration and building new customer relationships. Before joining the industry, Dr. Bocci did his postdoctoral studies at the Medical Research Council (MRC) in Cambridge, UK. He obtained his PhD from the University of Cambridge and is also a trained pharmacist.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:
Read the full story at http://www.prweb.com/releases/Marco_Bocci_Selexis/cell_line_development/prweb11344577.htm.
Copyright©2012 Vocus, Inc.
All rights reserved